These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy. Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687 [TBL] [Abstract][Full Text] [Related]
6. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089 [TBL] [Abstract][Full Text] [Related]
7. Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease. Ishigaki K; Murakami T; Nakanishi T; Oda E; Sato T; Osawa M Brain Dev; 2012 Feb; 34(2):98-102. PubMed ID: 21676566 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease. Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983 [TBL] [Abstract][Full Text] [Related]
9. Infantile-onset Pompe disease: a diagnosis not to miss. Dixon CA; Anderson JB; Ruddy RM; Cripe LH Pediatr Emerg Care; 2010 Apr; 26(4):293-5. PubMed ID: 20386415 [TBL] [Abstract][Full Text] [Related]
10. Use of the muscle volume analyzer to evaluate enzyme replacement therapy in late-onset Pompe disease. Sugai F; Kokunai Y; Yamamoto Y; Hashida G; Shimazu K; Mihara M; Inoue S; Sakoda S J Neurol; 2010 Mar; 257(3):461-3. PubMed ID: 19908083 [TBL] [Abstract][Full Text] [Related]
11. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961 [TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Klinge L; Straub V; Neudorf U; Voit T Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317 [TBL] [Abstract][Full Text] [Related]
13. Early pathologic changes and responses to treatment in patients with later-onset Pompe disease. Chien YH; Lee NC; Huang PH; Lee WT; Thurberg BL; Hwu WL Pediatr Neurol; 2012 Mar; 46(3):168-71. PubMed ID: 22353292 [TBL] [Abstract][Full Text] [Related]
14. Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease. Koeberl DD; Austin S; Case LE; Smith EC; Buckley AF; Young SP; Bali D; Kishnani PS FASEB J; 2014 May; 28(5):2171-6. PubMed ID: 24443373 [TBL] [Abstract][Full Text] [Related]
15. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease. Rafael Bretón Martínez J; Martínez AC J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333 [No Abstract] [Full Text] [Related]
16. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577 [TBL] [Abstract][Full Text] [Related]